Bispecific ADCs targeting the cancer, not the patient
Tuesday, July 28 at 15:00 BST | 16:00 CEST | 10:00 EDT | 07:00 PDT
Bispecific antibody-drug conjugates (ADCs) represent an emerging frontier in targeted cancer therapy, combining the precision of antibody-based targeting with the potency of cytotoxic payloads. By recognizing two distinct tumor-associated markers rather than one, bispecific ADCs can improve tumor selectivity, helping to distinguish cancer cells from healthy tissue and potentially reducing off-target effects. As the field advances, researchers are exploring innovative approaches to address longstanding challenges in efficacy, safety, and patient outcomes, making bispecific ADCs a rapidly growing area of interest in oncology research and drug development.
This SelectScience webinar introduces BiVictriX Therapeutics and its role as an early pioneer in bispecific, logic gated, ADCs. It will cover how ADCs are reshaping targeted cancer therapy and why bispecific targeting offers a route to improved tumor selectivity and reduced off-tumor toxicity. The presentation will also explore the key steps to take when designing a bispecific ADC, including target selection, antibody format, linker strategy, and payload choice, and how these decisions influence efficacy, safety, and clinical potential.
Speakers
Who should attend?
- Immuno-oncology researchers in academia and biopharma
What will this webinar cover?
- Understand the benefits of targeted cancer therapies and why ADCs can offer improved efficacy with reduced systemic toxicity
- Explain how logic-gating can improve tumor selectivity and increase efficacy
- Recognize the importance of ultra-high target specificity, as bispecific ADCs can target low-frequency double-positive tumor and healthy cell populations.
- How to tailor the ADC design to the indication, including format selection and payload choice
